ANNEXON INC

NASDAQ: ANNX (Annexon, Inc.)

最近更新时间: 4天之前, 12:51AM

4.83

-0.01 (-0.21%)

前收盘价格 4.84
收盘价格 4.80
成交量 1,715,725
平均成交量 (3个月) 1,320,760
市值 514,849,024
股市价格/股市净资产 (P/B) 1.58
52周波幅
3.86 (-20%) — 8.40 (73%)
利润日期 24 Mar 2025 - 28 Mar 2025
稀释每股收益 (EPS TTM) -1.03
总债务/股东权益 (D/E MRQ) 8.37%
流动比率 (MRQ) 21.81
营业现金流 (OCF TTM) -101.74 M
杠杆自由现金流 (LFCF TTM) -60.81 M
资产报酬率 (ROA TTM) -24.83%
股东权益报酬率 (ROE TTM) -42.20%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Annexon, Inc. 混合的 看涨

AIStockmoo 评分

-1.0
分析师共识 4.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 -2.5
技术振荡指标 -3.5
平均 -1.00

相关股票

股票 市值 DY P/E(TTM) P/B
ANNX 515 M - - 1.58
VIR 2 B - - 1.17
FTRE 2 B - - 1.08
SPRY 1 B - - 5.10
NTLA 1 B - - 1.08
OMER 498 M - - 8.44

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 0.50%
机构持股比例 106.10%

所有权

姓名 日期 持有股份
Logos Global Management Lp 30 Sep 2024 2,600,000
52周波幅
3.86 (-20%) — 8.40 (73%)
目标价格波幅
16.00 (231%) — 30.00 (521%)
30.00 (HC Wainwright & Co., 521.12%) 购买
23.00 (376.19%)
16.00 (Needham, 231.26%) 购买
平均值 23.00 (376.19%)
总计 2 购买
平均价格@调整类型 5.50
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 17 Dec 2024 30.00 (521.12%) 购买 4.88
15 Nov 2024 30.00 (521.12%) 购买 6.12
Needham 15 Nov 2024 16.00 (231.26%) 购买 6.12

该时间范围内无数据。

日期 类型 细节
13 Jan 2025 公告 Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
10 Jan 2025 公告 Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
07 Jan 2025 公告 Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
16 Dec 2024 公告 Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
16 Dec 2024 公告 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2024 公告 Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
15 Nov 2024 公告 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
14 Nov 2024 公告 Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
13 Nov 2024 公告 Annexon Biosciences to Present at the Jefferies London Healthcare Conference
21 Oct 2024 公告 Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
16 Oct 2024 公告 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
15 Oct 2024 公告 Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票